Wall Street Zen Downgrades Kenvue (NYSE:KVUE) to Hold

Key Points

• Wall Street Zen downgraded Kenvue to “Hold” from “Buy,” aligning with the broader analyst consensus: three analysts rate the stock a Buy and twelve rate it a Hold, with an average price target of $19.36.
• Kenvue’s second-quarter revenue rose 3% year over year to $3.96 billion, but EPS of $0.31 and revenue narrowly missed expectations. Inflation, tariffs and currency costs pressured margins despite higher pricing and volumes.
• Kenvue shares opened at $19.22, near the consensus target, while institutional investors own 97.64% of the stock. The pending Kimberly-Clark transaction is expected to close in the fourth quarter of 2026, although regulatory approvals remain outstanding.

Kenvue (NYSE:KVUE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Other research analysts also recently issued research reports about the stock. Barclays boosted their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Citigroup dropped their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a report on Wednesday, April 15th. UBS Group upped their price target on shares of Kenvue from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Thursday, July 16th. Finally, Zacks Research downgraded Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $19.36.

Kenvue Price Performance

Shares of KVUE opened at $19.22 on Friday. The business has a 50-day moving average of $18.77 and a 200-day moving average of $18.09. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The company has a market capitalization of $36.91 billion, a price-to-earnings ratio of 22.09, a price-to-earnings-growth ratio of 1.46 and a beta of 0.47. Kenvue has a 1 year low of $14.02 and a 1 year high of $21.95.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.17%. The business's revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.29 earnings per share. As a group, equities research analysts anticipate that Kenvue will post 1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Physician Wealth Advisors Inc. increased its stake in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter worth about $26,000. MV Capital Management Inc. bought a new position in shares of Kenvue during the 4th quarter worth about $28,000. CoreCap Advisors LLC grew its stake in shares of Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after buying an additional 591 shares during the period. Finally, Reflection Asset Management acquired a new stake in shares of Kenvue in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue News Summary

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Second-quarter net sales rose 3.0% year over year to $3.96 billion, supported by higher prices and volumes. Organic sales increased 1.6%, with growth across Self Care, Skin Health and Beauty, and Essential Health. Kenvue Posts Higher Profit, Sales as Turnaround Continues
• Positive Sentiment: Net income increased to $456 million from $420 million a year earlier, while adjusted diluted EPS reached $0.31 versus $0.29 in the prior-year quarter. Six-month operating cash flow was $1.2 billion and free cash flow was $1.0 billion. Kenvue Q2 net sales rise 3% as diluted EPS hits 24 cents
• Neutral Sentiment: The Kimberly-Clark transaction remains expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary conditions. Kenvue is withholding forward guidance because of the pending deal, limiting visibility for investors. How Reddit and Wall Street See Kenvue as Buyout Nears
• Negative Sentiment: Adjusted EPS of $0.31 fell short of the $0.32 consensus estimate, while revenue of $3.96 billion was slightly below the $3.97 billion forecast. The miss was unusual for Kenvue and contributed to the recent decline in the stock. Kenvue misses quarterly estimates as inflation, tariffs squeeze margins
• Negative Sentiment: Margins narrowed as inflation, tariffs and currency-related costs offset part of the benefit from pricing and volume gains, raising concerns about near-term profitability and the company’s turnaround execution. KVUE Q2 Earnings Miss Estimates as Margins Narrows Sales Rise

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source